90 related articles for article (PubMed ID: 18578373)
1. [Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].
Mayer J; Zácková D; Klamová H; Doubek M
Cas Lek Cesk; 2008; 147(4):206-10. PubMed ID: 18578373
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
3. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
4. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
5. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
6. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
7. [Chronic myeloid leukemia in the 21st century: biology and treatment].
Chávez-González MA; Ayala-Sánchez M; Mayani H
Rev Invest Clin; 2009; 61(3):221-32. PubMed ID: 19736811
[TBL] [Abstract][Full Text] [Related]
8. A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Park IJ; Lim YA; Lee WG; Park JS; Kim HC; Lee HJ; Cho SR
Cancer Genet Cytogenet; 2008 Sep; 185(2):106-8. PubMed ID: 18722880
[TBL] [Abstract][Full Text] [Related]
9. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
11. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
[TBL] [Abstract][Full Text] [Related]
12. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
14. [New views on the treatment of chronic myelocytic leukemia. Literature review].
Tóthová E
Vnitr Lek; 2002 Mar; 48(3):230-3. PubMed ID: 11968584
[TBL] [Abstract][Full Text] [Related]
15. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
16. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
17. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Komarova NL; Wodarz D
Cancer Res; 2009 Jun; 69(11):4904-10. PubMed ID: 19458080
[TBL] [Abstract][Full Text] [Related]
18. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
19. The short arm of chromosome 18 is a recurrent integration site of a supernumerary BCR/ABL gene fusion in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Grimm W; Siebert R
Cancer Genet Cytogenet; 2007 Dec; 179(2):156-8. PubMed ID: 18036405
[No Abstract] [Full Text] [Related]
20. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]